Explore the words cloud of the RapidEx project. It provides you a very rough idea of what is the project "RapidEx" about.
The following table provides information about the project.
Coordinator |
FABPULOUS BV
Organization address contact info |
Coordinator Country | Netherlands [NL] |
Project website | http://fabpulous.com/ |
Total cost | 1˙633˙750 € |
EC max contribution | 1˙633˙750 € (100%) |
Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
Code Call | H2020-SMEINST-2-2014 |
Funding Scheme | SME-2 |
Starting year | 2015 |
Duration (year-month-day) | from 2015-04-01 to 2017-10-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | FABPULOUS BV | NL (MAASTRICHT) | coordinator | 1˙633˙750.00 |
There is a pressing need for improvement of the diagnosis of acute myocardial infarction (AMI) for healthcare professionals (HCP). 1–1,5% of the population consult a physician each year with chest pain complaints. While the majority (60–80%) of these patients are sent to a hospital for further inspection, eventually AMI is diagnosed in only 8–18% of these cases. Consequently, a rapid, objective test that helps to better select patients suspected of AMI by HCPs would reduce the number of unnecessary hospital referrals and admissions, thereby saving costs and contributing to a more sustainable healthcare.
FABPulous (SME) is a medical device company spun out of Maastricht University in 2008. The core of the company is its innovative proprietary technology that allows a simple, robust and ultra-rapid diluted plasma preparation from a drop of blood. This offers great advantages over current technologies in point-of-care and home testing.
The CE-marked H-FABP True Rapid Test (H-FABP TRT) developed by FABPulous aids the HCP in ruling out AMI with a very high level of confidence. It is based on the heart-type fatty acid binding protein (H-FABP), which can be used as biomarker for AMI. With H-FABP TRT a physician is able to rule out the occurrence of an AMI for a large proportion of patients suspected of AMI. It is intended for use in both primary and emergency care.
In this project FABPulous seeks to medico-economically validate H-FABP TRT in primary (NetherlandsBelgium) and emergency care (UK) by performing two clinical trials. Outcomes of these studies lead to adoption of H-FABP TRT in medical guidelines and form the basis of a request for reimbursement towards health insurers. In this project FABPulous will improve the production process as well in order to decrease the cost price to €5 per test.
The addressable market in NW Europe alone amounts to at least 2 mln tests. The phased introduction plan leads to €8.6 mln revenue with a gross margin of €6.5 mln in 2018.
Clinical study protocol emergency care trial | Documents, reports | 2019-04-15 17:08:30 |
Take a look to the deliverables list in detail: detailed list of RapidEx deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RAPIDEX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RAPIDEX" are provided by the European Opendata Portal: CORDIS opendata.
European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development
Read MoreProject on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life
Read More